poisar

Stocks · News reference

Sinovac Biotech H1 EPS $(0.84) Down From $0.06 YoY, Sales $147.079M Up From $130.270M YoY

Aug 17, 2026, 12:18 PMBenzinga Newsdesk

Sinovac Biotech (NASDAQ:SVA) reported quarterly losses of $(0.84) per share. This is a 1500 percent decrease over earnings of $0.06 per share from the same period last year. The company reported $147.079 million in

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

SVA
Source
benzinga
Observed
Aug 17, 2026, 12:18 PM
Checked
Aug 17, 2026, 12:18 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 7, 2026, 9:54 AMResearchandmarkets.Com

    Global Influenza Vaccine Market Report, 2026 Edition - Profiles GlaxoSmithKline, Pfizer, Sanofi, Moderna, and 9 Other Players

    The global influenza vaccine market was valued at US$8.96 billion in 2024 and is projected to reach US$13.32 billion by 2030, growing at a 7% CAGR. Market expansion is driven by rising public health awareness, an aging population, government immunization programs, and increased R&D investment. Quadrivalent and inactivated vaccines lead the market, while cell-based technologies and pediatric segments show fastest growth. Key players include GlaxoSmithKline, Pfizer, Sanofi, Moderna, and others.

    Read original at globenewswire-inc
    GSKPFEMRNASVASNY